File this under ‘unintended consequences.’ A number of health care organizations are complaining that a final guideline the US Food and Drug Administration recently released for naming both biologic medicines and identical, but lower-cost biosimilar versions will cost the health care system billions of dollars in technology costs. How so? The guideline is designed to make…
Make Better Decisions with DrugPatentWatch
Related Posts:
Biosimilar Naming: Navigating the Complex World of… Drug Prices and Generic Competition: A Comprehensive… Decoding Drug Pricing Models: A Strategic Guide to… The Biosimilar Landscape: An Overview of Regulatory… List of NIH-Licensed Technologies The Patent Cliff's Shadow: Impact on Branded… The Comprehensive Science and Art of Pharmaceutical… Differences in rates of switchbacks after switching… Navigating the Minefield: Critical Mistakes to Avoid… Branded Generics: What They Are and Why They're Profitable Strategies for Pricing Generic Drugs Top 5 Challenges Faced By Biosimilars: Navigating… Market access of gene therapies across Europe, USA,… Evaluating innovative drug portfolios and preparing… Ten years of biosimilars in Europe: development and… Customer Success: How do we identify generic… The Transformation of the US Generic Drug Industry… How to Optimize Generic Drug Production Costs: A… Exploring Biosimilars as a Drug Patent Strategy Finding Hidden Treasures in Old Drugs: The… Measuring the knowledge translation and convergence… Affordability and availability of off-patent drugs… Finding and Evaluating Branded and Generic Market… Drug Spending in the US: Where the Money Actually Goes